• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Monday's Intraday Session

    3/25/24 1:30:58 PM ET
    $AKAN
    $ATNF
    $CYTO
    $IVVD
    Medicinal Chemicals and Botanical Products
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AKAN alert in real time by email

    Gainers

    • Landos Biopharma (NASDAQ:LABP) shares rose 173.9% to $21.45 during Monday's regular session. The market value of their outstanding shares is at $66.8 million. The company's, Q4 earnings came out 2 days ago.
    • Altamira Therapeutics (NASDAQ:CYTO) stock moved upwards by 30.63% to $2.26. The market value of their outstanding shares is at $4.1 million.
    • XTL Biopharmaceuticals (NASDAQ:XTLB) shares increased by 28.24% to $3.36. The company's market cap stands at $18.3 million.
    • Nkarta (NASDAQ:NKTX) shares moved upwards by 23.87% to $11.05. The company's market cap stands at $542.2 million. As per the news, the Q4 earnings report came out 2 days ago.
    • Sagimet Biosciences (NASDAQ:SGMT) stock rose 23.05% to $5.55. The market value of their outstanding shares is at $177.0 million. The company's, FY earnings came out today.
    • Molecular Templates (NASDAQ:MTEM) shares moved upwards by 21.62% to $2.25. The company's market cap stands at $12.0 million.

    Losers

    • Trxade Health (NASDAQ:MEDS) stock decreased by 48.6% to $12.38 during Monday's regular session. The company's market cap stands at $14.9 million.
    • SINTX Techs (NASDAQ:SINT) stock declined by 48.01% to $0.05.
    • Akanda (NASDAQ:AKAN) stock decreased by 34.42% to $0.16. The market value of their outstanding shares is at $1.4 million.
    • Invivyd (NASDAQ:IVVD) stock declined by 23.06% to $3.35. The company's market cap stands at $398.7 million.
    • 180 Life Sciences (NASDAQ:ATNF) stock fell 19.88% to $2.22. The market value of their outstanding shares is at $1.6 million.
    • Kineta (NASDAQ:KA) shares decreased by 16.88% to $0.54. The market value of their outstanding shares is at $5.6 million. The company's, Q4 earnings came out 2 days ago. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $AKAN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AKAN
    $ATNF
    $CYTO
    $IVVD

    CompanyDatePrice TargetRatingAnalyst
    Sagimet Biosciences Inc.
    $SGMT
    2/3/2026$27.00Buy
    Guggenheim
    Sagimet Biosciences Inc.
    $SGMT
    1/28/2026$8.00Equal Weight
    Barclays
    Invivyd Inc.
    $IVVD
    12/22/2025$10.00Buy
    BTIG Research
    Invivyd Inc.
    $IVVD
    11/25/2025Buy → Hold
    D. Boral Capital
    Invivyd Inc.
    $IVVD
    10/6/2025$10.00Overweight
    Cantor Fitzgerald
    Sagimet Biosciences Inc.
    $SGMT
    8/11/2025$28.00Outperform
    Wedbush
    Sagimet Biosciences Inc.
    $SGMT
    8/7/2025$29.00Buy
    H.C. Wainwright
    Sagimet Biosciences Inc.
    $SGMT
    7/24/2025$28.00Buy
    Canaccord Genuity
    More analyst ratings

    $AKAN
    $ATNF
    $CYTO
    $IVVD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Invivyd to Host Fourth Quarter and Full-Year 2025 Financial Results and Corporate Update Conference Call on March 5, 2026

    NEW HAVEN, Conn., March 02, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (NASDAQ:IVVD), a biopharmaceutical company focused on delivering protection from serious viral infectious diseases, today announced that it will host a conference call on Thursday, March 5, 2026, at 8:30 a.m. ET to discuss its fourth quarter and full-year 2025 financial results and provide a corporate update. Interested parties may join the live webcast by visiting this link. Analysts wishing to participate in the question-and-answer session should use this link. Those who plan on participating are advised to join 15 minutes prior to the start time. A recording of the webcast will be available on the company's investor rel

    3/2/26 4:10:00 PM ET
    $IVVD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    NEW HAVEN, Conn., March 02, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (NASDAQ:IVVD) today announced that on March 1, 2026, Invivyd granted four newly hired non-executive employees options to purchase an aggregate of 192,000 shares of its common stock, each as a material inducement for each employee's entry into employment with Invivyd. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4) and pursuant to the Invivyd, Inc. 2026 Inducement Plan. The options have a per share exercise price of $1.69, representing the closing price of Invivyd's common stock on February 27, 2026, the last trading date prior to the date of grant. Each option vests over four years, with 25% of t

    3/2/26 4:01:00 PM ET
    $IVVD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    XTL Announces Receipt of Staff Delist Determination from Nasdaq and Plans to Request Hearing

    RAMAT GAN, ISRAEL, Feb. 27, 2026 (GLOBE NEWSWIRE) -- XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB) (TASE:XTLB.TA) (the "Company" or "XTL"), announced today that it has received a letter (the "Letter") from The Listing Qualifications Department (the "Staff") of The Nasdaq Stock Market LLC ("Nasdaq"), dated February 25, 2026, notifying the Company of the Staff's belief, based upon its review of the Company and pursuant to Nasdaq Listing Rule 5101, that the Company is a "public shell", and that continued listing of the Company's American Depositary Shares ("ADSs") is no longer warranted. The Company intends to request a hearing (the "Hearing") to appeal the delisting process before a Nasdaq Heari

    2/27/26 4:30:00 PM ET
    $XTLB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKAN
    $ATNF
    $CYTO
    $IVVD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Guggenheim initiated coverage on Sagimet Biosciences with a new price target

    Guggenheim initiated coverage of Sagimet Biosciences with a rating of Buy and set a new price target of $27.00

    2/3/26 7:59:13 AM ET
    $SGMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Barclays initiated coverage on Sagimet Biosciences with a new price target

    Barclays initiated coverage of Sagimet Biosciences with a rating of Equal Weight and set a new price target of $8.00

    1/28/26 7:18:50 AM ET
    $SGMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BTIG Research initiated coverage on Invivyd with a new price target

    BTIG Research initiated coverage of Invivyd with a rating of Buy and set a new price target of $10.00

    12/22/25 8:39:25 AM ET
    $IVVD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AKAN
    $ATNF
    $CYTO
    $IVVD
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Moyes Jay M bought $2,910 worth of shares (1,000 units at $2.91), increasing direct ownership by 33% to 4,000 units (SEC Form 4)

    4 - Sintx Technologies, Inc. (0001269026) (Issuer)

    2/25/26 9:00:02 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    Director Anderson Mark Lewis bought $9,060 worth of shares (3,000 units at $3.02), increasing direct ownership by 20% to 18,000 units (SEC Form 4)

    4 - Sintx Technologies, Inc. (0001269026) (Issuer)

    2/19/26 9:00:04 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    Large owner Hrt Financial Lp bought $40,650 worth of Class A Shares (29,036 units at $1.40) and sold $10,150 worth of Class A Shares (7,868 units at $1.29) (SEC Form 4)

    4 - AKANDA CORP. (0001888014) (Issuer)

    1/20/26 2:07:19 PM ET
    $AKAN
    Medicinal Chemicals and Botanical Products
    Health Care

    $AKAN
    $ATNF
    $CYTO
    $IVVD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Moyes Jay M bought $2,910 worth of shares (1,000 units at $2.91), increasing direct ownership by 33% to 4,000 units (SEC Form 4)

    4 - Sintx Technologies, Inc. (0001269026) (Issuer)

    2/25/26 9:00:02 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    Chief Legal & Admin. Officer Rozek Elizabeth was granted 44,000 units of Series A Common Stock, increasing direct ownership by 23% to 234,959 units (SEC Form 4)

    4 - Sagimet Biosciences Inc. (0001400118) (Issuer)

    2/20/26 4:43:57 PM ET
    $SGMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Medical Officer Martins Eduardo Bruno was granted 44,000 units of Series A Common Stock, increasing direct ownership by 43% to 147,296 units (SEC Form 4)

    4 - Sagimet Biosciences Inc. (0001400118) (Issuer)

    2/20/26 4:42:48 PM ET
    $SGMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKAN
    $ATNF
    $CYTO
    $IVVD
    SEC Filings

    View All

    SEC Form 6-K filed by XTL Biopharmaceuticals Ltd.

    6-K - XTL BIOPHARMACEUTICALS LTD (0001023549) (Filer)

    2/27/26 4:34:26 PM ET
    $XTLB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Akanda Corp.

    6-K - AKANDA CORP. (0001888014) (Filer)

    2/27/26 3:57:00 PM ET
    $AKAN
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 6-K filed by XTL Biopharmaceuticals Ltd.

    6-K - XTL BIOPHARMACEUTICALS LTD (0001023549) (Filer)

    2/24/26 4:05:06 PM ET
    $XTLB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKAN
    $ATNF
    $CYTO
    $IVVD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Nkarta Inc.

    SC 13G - Nkarta, Inc. (0001787400) (Subject)

    12/13/24 5:02:47 PM ET
    $NKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Invivyd Inc.

    SC 13D/A - Invivyd, Inc. (0001832038) (Subject)

    12/12/24 4:39:09 PM ET
    $IVVD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Molecular Templates Inc.

    SC 13G/A - Molecular Templates, Inc. (0001183765) (Subject)

    11/18/24 9:49:56 PM ET
    $MTEM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKAN
    $ATNF
    $CYTO
    $IVVD
    Leadership Updates

    Live Leadership Updates

    View All

    XTL Announces Receipt of Staff Delist Determination from Nasdaq and Plans to Request Hearing

    RAMAT GAN, ISRAEL, Feb. 27, 2026 (GLOBE NEWSWIRE) -- XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB) (TASE:XTLB.TA) (the "Company" or "XTL"), announced today that it has received a letter (the "Letter") from The Listing Qualifications Department (the "Staff") of The Nasdaq Stock Market LLC ("Nasdaq"), dated February 25, 2026, notifying the Company of the Staff's belief, based upon its review of the Company and pursuant to Nasdaq Listing Rule 5101, that the Company is a "public shell", and that continued listing of the Company's American Depositary Shares ("ADSs") is no longer warranted. The Company intends to request a hearing (the "Hearing") to appeal the delisting process before a Nasdaq Heari

    2/27/26 4:30:00 PM ET
    $XTLB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SINTX Technologies Appoints Ryan Elmore President to Lead Channel Expansion of Silicon Nitride Biomaterial Platforms

    Appointment supports acceleration of revenue opportunities from SiNERGY™ silicon nitride devices and antipathogenic fibrous material technologies SALT LAKE CITY, Utah, Feb. 18, 2026 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ:SINT) ("SINTX" or the "Company"), an advanced ceramics and biomaterials company focused on silicon nitride (SiN) solutions for medical and other high-value applications, today announced the appointment of Ryan Elmore as President of SINTX Technologies, Inc., effective March 16, 2026. Mr. Elmore most recently served as Core Business Director at Invibio, a division of Victrex plc. With more than 15 years of experience in advanced biomaterials and medical dev

    2/18/26 8:30:00 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    Invivyd to Host Webcast on the REVOLUTION Clinical Program for VYD2311, a Vaccine-Alternative Antibody to Prevent COVID

    NEW HAVEN, Conn., Oct. 28, 2025 (GLOBE NEWSWIRE) -- WHAT: Invivyd, Inc. (NASDAQ:IVVD) is hosting the previously announced live webcast to present an overview of the company's REVOLUTION clinical program, Invivyd's development program for VYD2311, a vaccine-alternative monoclonal antibody candidate for the prevention of COVID. The session will feature key members of the Invivyd team. WHEN: Thursday, October 30, 2025, at 8:30 a.m. ET WHERE: Listeners are advised to join the webcast via the following link 15 minutes prior to the start time. A replay of the webcast will be available via the investor relations section of the company's website approximately two hours after the conclusion of

    10/28/25 7:01:00 AM ET
    $IVVD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AKAN
    $ATNF
    $CYTO
    $IVVD
    Financials

    Live finance-specific insights

    View All

    Invivyd to Host Fourth Quarter and Full-Year 2025 Financial Results and Corporate Update Conference Call on March 5, 2026

    NEW HAVEN, Conn., March 02, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (NASDAQ:IVVD), a biopharmaceutical company focused on delivering protection from serious viral infectious diseases, today announced that it will host a conference call on Thursday, March 5, 2026, at 8:30 a.m. ET to discuss its fourth quarter and full-year 2025 financial results and provide a corporate update. Interested parties may join the live webcast by visiting this link. Analysts wishing to participate in the question-and-answer session should use this link. Those who plan on participating are advised to join 15 minutes prior to the start time. A recording of the webcast will be available on the company's investor rel

    3/2/26 4:10:00 PM ET
    $IVVD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SINTX Reports Pivotal Third Quarter Business Update and Financial Highlights Driven by FDA Clearance, Product and IP Portfolio Expansions and Increased Operational Efficiencies

    Company underscores its strengthened liquidity, cost reductions, and first revenue recorded from OsseoSculpt™  SALT LAKE CITY, Utah, Nov. 13, 2025 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ:SINT) ("SINTX" or the "Company"), an advanced ceramics and biomaterials company focused on silicon-nitride–based medical technologies, today provided a business update reporting third quarter financial results in conjunction with the filing the Company's Form 10-Q for the quarter ended September 30, 2025. During the third quarter and subsequent weeks, SINTX advanced a focused commercialization plan centered on infection-resistant silicon nitride devices and polymer composites, while tighteni

    11/13/25 8:00:00 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    Invivyd to Host Third Quarter 2025 Financial Results and Corporate Update Call on November 6, 2025

    NEW HAVEN, Conn., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (NASDAQ:IVVD), a biopharmaceutical company focused on delivering protection from serious viral infectious diseases, today announced that it will host a conference call on Thursday, November 6, 2025, at 8:30 a.m. ET to discuss its third quarter 2025 financial results and provide a corporate update. Interested parties may join the live webcast by visiting this link and are advised to log in approximately 15 minutes prior to the start of the call. A recording of the webcast will be available on the company's investor relations website shortly after the event. About Invivyd Invivyd, Inc. (NASDAQ:IVVD) is a biopharmaceutical c

    11/3/25 4:01:00 PM ET
    $IVVD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care